Paul Capital Healthcare leads investment to provide more than $100 million to UCB S.A.

Paul Capital Healthcare today announced that it has led an investment to provide more than $100 million to UCB S.A. in exchange for certain payments relating to the sales of products marketed by third parties. The underlying third party products (which are non-core to UCB) are leading brands in their therapeutic fields.

"This transaction underscores Paul Capital Healthcare's continued ability to help innovative companies access transformative growth capital," said Dr. Ken Macleod in Paul Capital Healthcare's London office. "These are quality products that have the support of strong marketing partners. We believe that this transaction will provide benefit to both Paul Capital Healthcare and UCB."

"As evidenced by this investment, Paul Capital Healthcare is committed to working with companies to tailor transactions that meet their near-term financial needs and long-term growth objectives," said Andrew Rubinstein in Paul Capital Healthcare's New York office. "Our approach is an attractive alternative to traditional equity and debt financing for a variety of pharmaceutical, biotechnology and medical device companies in the United States, Europe and Asia, including major global pharmaceutical companies such as UCB."